anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: A post marketing surveillance (PMS) system based on a network and a method thereof are provided to obtain clinical test statistics through real-time monitoring, thereby reducing time and costs required for safety verification. CONSTITUTION: A portal service unit (210) enables one portal site to provide other sites including a research page by offering a menu capable of selecting medicines to a main page and linking the main page to the research page which inputs clinical test data according to the selection of the menu. A data storage unit (220) collects and classifies the clinical test data. The data storage unit stores the clinical test data in a database unit. A data processing unit (230) generates statistical data by processing the clinical test data and transmits the statistical data to a terminal of a research manager. A report writing unit (240) writes an annual PMS report based on the statistical data. [Reference numerals] (210) Portal service unit; (220) Data storage unit; (230) Data processing unit; (240) Report writing unit; (250) Authorization request unit; (260) Change record managing unit; (270) Control unit
It can be stated that single agent DaunoXome seems associated with a level of anti-leukemic activity at least equivalent to the conventional drugs available. In addition, the safety profile of DaunoXome either as a single agent either as a combination with Ara-C seems improved with respect to the conventionally administered anthracyclines. Therefore, it seems warranted to further explore the anti-leukemic activity, the toxicity and the long term results of DaunoXome as a treatment for AML in association with Ara-C against the parent compound daunorubicin. In particular, we propose a study to evaluate standard 3+7 schedule versus the same schedule with DaunoXome instead of daunorubicine as front line treatment in AML patients older than 60 years. Patients achieving a CR will receive a consolidation cycle with the same drugs at the same doses. After consolidation, patients in CR will be randomized to receive a maintenance treatment with low-dose Ara-C plus Atra versus no treatment.
GERD is a significant public health problem and when it is severe it may have a considerable impact on patients' QOL. Relatively new treatments such as proton pump inhibitors (PPI) and laparoscopic fundoplication (wrapping or gathering the stomach around the lower end of the esophagus to reduce or prevent reflux) are now available. Patient derived outcomes such as QOL and satisfaction are rarely taken into consideration when evaluating such new treatments. Outcome analysis of the results of medical and surgical treatments using an ongoing database of patients will enhance our ability to treat patients with GERD.

This study's goal is to build a database to collect the outcome information on patients who are having medical or surgical treatment of GERD. In addition we want to measure standard outcomes such as morbidity, mortality, medication use and patient derived outcomes such as general and disease specific QOL, and patient satisfaction with the treatment. We also want to assess if and how long QOL is improved by medical and surgical treatment methods. In addition we want to see if low QOL scores on medical treatment as well as the standard medical criteria can help to identify which patients may benefit from surgical (an operation) rather than the medical treatment. It is hoped that we can also identify which factors might predict or help to determine which patients will have failure of both medical and surgical treatments of GERD. Using this information we want to identify if a psychological profile done before treatment will influence or predict the outcomes of treatment.
PURPOSE: The Core Outcome Measures Index (COMI) is a short, multidimensional instrument translated into several languages that covers five domains recommended in the assessment of outcome in patients with low-back and neck pain. The purpose of this study was to cross-culturally adapt the COMI from English to Czech language and to test the face and construct validity and reproducibility of its results in patients with low-back and neck pain.
METHODS: Participants (n = 125) were included from primary and secondary care. The participants reported moderate pain and disability levels. All participants filled in the COMI forms before and after surgery. Descriptive statistics, Wilcoxon paired test, Crombach's alpha, principal component analysis and information entropy calculation were used.
RESULTS: The instrument was successfully forward and back-translated. It can be seen that the questionnaire applied as part of our intervention study produces answers with a sufficient degree of variability and with a satisfactory degree of representation of extreme values. It can be also seen that the questionnaire can diagnose an objectively occurring change associated with the surgeon within the intervention procedure. Our other findings support the idea of ​​a possible reduction in the number of questions that measure the same latent variable. Our investigations also showed that it is possible to reduce the range of the point scale of the perception of pain to 5 degrees of intensity and thus unify the range with the other questions.
CONCLUSION: The Czech COMI shows acceptable properties and is thus suitable to use as a short instrument for measuring important domains in patients with low-back and neck pain.
PURPOSE:To enable a silicone rubber to be bonded firmly even under highly humid conditions to a metal with an excellent durability by bonding the silicone rubber to the surface of the copolymer layer of three specific compds. in combination formed on the surface of the metal. CONSTITUTION:A copolymer layer of a compd. of formula I [Z is o- dicarboxyphenyl (anhydride) of 1, 2-dicarboxyethyl ] and a compd. of formula II (R3 is H or CH3; and Y is lower alkoxycarbonyl, lower alkylcarbonyloxy, halogen, or lower alkoxy) is formed on the surface of a metal, followed by the formation on the surface of the copolymer layer of another copolymer layer of the compd. of formula II and a compd. of formula III (R1 is H or CH3; R2 is H or lower alkyl; and X is lower alkyl), to the surface of which a silicone rubber is then bonded. According to the foregoing procedure, the silicone rubber can be very firmly bonded to the metal with an excellent durability while enabling the long-time use of the resulting product even under highly humid conditions. Accordingly, the procedure can be used for bonding a silicone rubber to a dental plate, etc.
OBJECTIVES: To investigate the accuracy of ultrasound in the quantification of tumor thickness (TT) and depth of invasion (DOI) of oral potentially malignant disorders and oral squamous cell carcinoma.
MATERIALS AND METHODS: A systematic review search was conducted in PubMed, Scopus, and Web of Science to answer the PICO question: "What is the correlation and the mean difference between ultrasound and histopathological assessment of tumor thickness and depth of invasion in patients with oral squamous cell carcinoma and oral potentially malignant disorders? The risk of bias was assessed, meta-analysis and trial sequential analysis was conducted on the available quantitative data, followed by trial sequential analysis.
RESULTS: Of 2089 results, 48 studies were considered suitable for inclusion. Meta-analysis showed a low heterogeneity for tumor thickness mean difference (I2 = 0.00 %) with an overall standardized mean difference (SMD) of 0.13 (95 % CI: -0.07 to 0.33, p = 0.214). Tumor thickness correlation showed high heterogeneity (I2 = 93.41 %). For depth of invasion, the mean difference had moderate heterogeneity (I2 = 8.98 %) with an overall SMD of 0.27 (95 % CI: 0.06 to 0.48, p = 0.013). However, correlation analysis showed moderate heterogeneity (I2 = 56.22 %). Trial sequential analysis confirmed the tumor thickness results but indicated more studies are required for depth of invasion to meet the required information size.
CONCLUSION: There were no statistically significant differences between the results of ultrasound and histological examination, the clinical use of this device cannot yet be confirmed.
PROBLEM TO BE SOLVED: To provide a method for preparing an Aloe arborescens Mill. var. nat Chinese herb medicine which contains all medicinal efficacy ingredients, exhibits therapeutic effects as a universal medicine, does not contain impurities such as residues, scarcely has a bitter taste, is easily drinkable, and has excellent preservability by using the raw leaves (jelly-like mesophyll placed between the skins) of the Aloe arborescens Mill. var. nat. SOLUTION: This method for preparing the Aloe arborescens Mill. var. nat Chinese herb medicine which can be preserved at a low temperature of 2 to 3 deg.C for three weeks comprises cutting off the petioles, tips and thorns of the raw leaves of the Aloe arborescens Mill. var. nat, directly slicing the raw leaves into a pan in a desired width, adding a prescribed amount of water, boiling the sliced raw leaves to extract the Aloe arborescens Mill. var. nat, precipitating residues in the obtained aloe extract, and then filtering off the precipitated residues.
PURPOSE:To provide the subject remedy for trichophytosis composed of Japanese apricot pulp extraction, aloenin and an aqueous ethanol solution, free from side effects and capable of prolonged administration. CONSTITUTION:A remedy for trichophytosis containing 1.5-4.0 pts.wt., preferably 2.0-3.5 pts.wt. solid matter aloenin obtained by grinding and pressing a mixture composed of 100 pts.wt. 30% aqueous ethanol solution, 10-15 pts.wt., preferably 13-14 pts.wt. Japanese apricot pulp extract and naturally dried mesophyll of Aloe arborescens Mill., carrying out centrifugation and heating the resultant liquid material at <=60 deg.C. Provided that citric acid is contained in an amount of 1.5 4.0 pts.wt. on sodium salt base in 10-15 pts.wt. Japanese apricot pulp extract. To the aloenin solid raw material, the Japanese apricot pulp extract and the aqueous ethanol solution are added and the resultant mixture is stirred using a mixer. The obtained liquid is allowed to stand at a cold and dark place and the supernatant is collected, thus preparing the objective remedy.
Participants will receive SC bermekimab Dose 2 qw from Week 0 through Week 15. At Week 16, participants who achieve an eczema area and severity index (EASI)-75 response (responders) will be rerandomized either to continue to receive bermekimab Dose 2 qw, or to receive bermekimab Dose 1 qw, through Week 31 and participants who do not achieve an EASI-75 response (non responders) will continue to receive bermekimab Dose 2 qw through Week 31.
FIELD: medicine, gastroenterology, pharmacy. SUBSTANCE: solid medicinal formula oral administration involves nucleus consisting of omeprazole or its mixture with pharmaceutically acceptable alkaline agent, or a mixture of omeprazole alkaline salt with pharmaceutically acceptable alkaline agent. Nucleus is covered with at least one auxiliary envelope made of water-soluble and rapidly suspended in water. Enteric-soluble coating is covered on this envelope. Preferably, auxiliary envelope consists of one or more compounds taken from the group involving magnesium oxide, magnesium hydroxide and composition compounds of the formulas: Al 2 O 3 •6MgO•CO 2 •12H 2 O or MgO•H 2 O 3 •2SiO 2 •nH 2 O where: n - fractional number less 2, more preferably consisting of hydroxypropylcellulose, hydroxymethylcellulose or polyvinylpyrrolidone. In part, nucleus has a mixture of omeprazole and alkaline buffer compound providing micromedium pH value 7-12 around omeprazole. Alkaline agent is one or some compounds taken from the group involving aluminium oxide, hydroxide, aluminium, calcium, sodium or potassium carbonate, phosphate or citrate and composition compounds of the formulas Al 2 O 3 •6MgO•CO 2 •12H 2 O or MgO•Al 2 O 3 •2SiO 2 •nH 2 O where: n - fractional number less 2. Preferably - sodium, potassium, magnesium, calcium or ammonium salt of omeprazole. Enteric-soluble coating consists of the compound taken from the group involving hydroxypropylmethylcellulose phthalate, cellulose acetate phthalate, copolymer of methacrylic acid with methylmethacrylate and polyvinylpyrrolidone (preferably). Auxiliary envelope can contain pH-buffering alkaline compounds at humidity 1.5%, not above. The proposed medicinal formula is used for gastric secretion regulation and gastroenteric cytoprotective effect providing. EFFECT: enhanced effectiveness of composition. 10 cl, 8 tbl
This invention embodies a method to increase bioavailabilty of molecular hydrogen to both external and internal tissue surfaces including but not limited to epidermis external (e.g. skin) and epidermis internal (e.g. intraocular, vulvar, vaginal and internal reproductive structures, mouth, throat, esophegus , stomach , duodenum and colon).  secondary bioavailablity via extended assimilation e.g. via the lung as a result of slow release of hydrogen from bubbles in the stomach which are aspirated into the lung is a derivative of the primary use of this invention and therefore an aspect of it. Another embodiment is the use of this invention to make molecular hydrogen available in a delivery medium which does not carry with it the regulatory impediments and insurance and safety of use liabilities as found in the state of the art which is free molecular hydrogen in uncompressed free gas or hyperbaric compressed gas state. The state of the art is also restricted by the homeopathic concentrations available in "hydrogen water" or a limited use as an "in situ" derivative of lactulose within the bowel. This invention provides a solution to these problems.
The electric tooth brush for inspecting the dental cleaning process, comprises a UV light emitting diode (16) connected at a battery, which is inserted into a cavity of the brush head (12), and a handle part having a moving drive and a brush attachment (10). The brush head has a photocell. A ring shaped display light arranged in brush neck (14) or -handle is activated by the photocell, which is in connection with a control circuit in a defined intensity of the reflected UV light. The diode is connected over electric contacts on the handle part and on the brush attachment. The electric tooth brush for inspecting the dental cleaning process, comprises a UV light emitting diode (16) connected at a battery, which is inserted into a cavity of the brush head (12), and a handle part having a moving drive and a brush attachment (10). The brush head has a photocell. A ring shaped display light arranged in brush neck (14) or -handle is activated by the photocell, which is in connection with a control circuit in a defined intensity of the reflected UV light. The diode is connected over electric contacts on the handle part and on the brush attachment arranged on current source of the moving drive, and is water tightly covered by a glass or transparent plastic. The wavelength of the light of the diode is 300 nm.
ZEGALOGUE contains dasiglucagon hydrochloride, which is a glucagon analog and an antihypoglycemic agent. Dasiglucagon is comprised of 29 amino acids. The molecular formula of dasiglucagon (anhydrous, free-base) is C 152H 222N 38O 50, and its molecular mass is 3382 g/mol (anhydrous, free-base). Dasiglucagon hydrochloride has the following chemical structure: 

ZEGALOGUE injection is a preservative free, sterile, aqueous, clear, and colorless solution for subcutaneous use in a single-dose prefilled syringe and an autoinjector. Each prefilled syringe and autoinjector contains 0.63 mg of dasiglucagon provided as dasiglucagon hydrochloride, which is a salt with 3 - 5 equivalents of hydrochloride, and contains the following inactive ingredients: 3.82 mg tromethamine, 6.44 mg sodium chloride, and water for injection. Hydrochloric acid and/or sodium hydroxide may have been added to adjust pH to 6.5.
Before initiating therapy, a detailed history and physical examination should be made.

Tegretol should be used with caution in patients with a mixed seizure disorder that includes atypical absence seizures, since in these patients Tegretol has been associated with increased frequency of generalized convulsions (see INDICATIONS AND USAGE).

Therapy should be prescribed only after critical benefit-to-risk appraisal in patients with a history of cardiac conduction disturbance, including second- and third-degree AV heart block; cardiac, hepatic, or renal damage; adverse hematologic or hypersensitivity reaction to other drugs, including reactions to other anticonvulsants; or interrupted courses of therapy with Tegretol.

AV heart block, including second- and third-degree block, have been reported following Tegretol treatment. This occurred generally, but not solely, in patients with underlying EKG abnormalities or risk factors for conduction disturbances.

Hepatic effects, ranging from slight elevations in liver enzymes to rare cases of hepatic failure have been reported (see ADVERSE REACTIONS and PRECAUTIONS, Laboratory Tests). In some cases, hepatic effects may progress despite discontinuation of the drug. In addition, rare instances of vanishing bile duct syndrome have been reported. This syndrome consists of a cholestatic process with a variable clinical course ranging from fulminant to indolent, involving the destruction and disappearance of the intrahepatic bile ducts. Some, but not all, cases are associated with features that overlap with other immunoallergenic syndromes, such as multiorgan hypersensitivity (DRESS syndrome) and serious dermatologic reactions. As an example, there has been a report of vanishing bile duct syndrome associated with SJS and in another case an association with fever and eosinophilia.

Since a given dose of Tegretol suspension will produce higher peak levels than the same dose given as the tablet, it is recommended that patients given the suspension be started on lower doses and increased slowly to avoid unwanted side effects (see DOSAGE AND ADMINISTRATION).

Tegretol suspension contains sorbitol and, therefore, should not be administered to patients with rare hereditary problems of fructose intolerance.
Hair is waved by curling it around a curler having a diameter greater than 10 mm, treating it with a reducing agent, e.g. ammoniumthioglycolate, terminating the treatment with the reducing agent by the application of a neutralising agent, e.g. hydrogenperoxide, and subsequently rinsing and drying it, a force sufficient to produce an elongation of at least 0.5% being imparted to the hair after winding on the curler and before or during the treatment with the reducing agent.  The force producing elongation may be maintained until after the rinsing and is preferably maintained until a few minutes before the end of the drying operation.  When the drying has been completed the hair may be left at ambient temperature for several minutes and the curler then removed.  The force producing elongation may be arranged to produce an elongation proportional to the diameter of the curler and inversely proportional to the diameter of the hairs being treated. The elongation may be imported to the hair by means of a curler in the form of two shell halves each having a clamp for securing the hair to the shell and a pair of conical inserts adapted to be screwed towards one another to effect separation of the two shell halves.
PROBLEM TO BE SOLVED: To obtain an aqueous medicinal composition which possesses a specific range of gel transition temperature T, shows a liquid state at a temperature lower than T and a gel state at a temperature of T or above and exerts improved medicine retentivity in the diseased part by including a gel formable substance. SOLUTION: By including a gel formable substance (e.g. a polyvinylacetal diethylaminoacetate or the like), the aqueous medicinal composition which possesses gel transition temperature T (G) in a range of 5-40 deg.C and shows a liquid state at a temperature lower than the above T (G) and a gel state at a temperature of T (G) or above is obtained. The above gel formable substance is included in an amount capable of controlling the temperature T (G) in the above temperature range, preferably at 10-37 deg.C. For example, in the case of a polyvinyl acetal diethylamino-acetate, it is included in a proportion of 0.1-15 wt.%, preferably 0.1-15 wt.%, based on the composition. As the medicinal composition, the composition for oral cavity (particularly a peridontal disease therapeutic agent, a hyperesthesia therapeutic agent or a dental calculus suppressive agent) is preferably illustrated.
Congenital heart disease (CHD) and the need for life-saving heart surgery and intensive care during infancy may have effects on infant behavior and development. Children who require open heart surgery before their first birthday are vulnerable to developmental delays, especially related to motor skills (mobility) in the first year of life. Early delays in gross motor functioning (e.g., rolling, crawling, walking) have implications for learning and psychosocial development through adulthood. To date, no interventions to improve the gross motor functioning of children born with CHD have been developed. The purpose of this study is to learn more about developmental behaviors and to examine changes in developmental progress related to motor activities among a group of infants who received open heart surgery within the first three months of life. Activities will be tailored based on the individual infant's motor ability and medical status.
INTRODUCTION: Face-lifting surgeries were once common among individuals over 60 years old due to skin laxity, but recent trends favor thread lifting in this age group. Understanding dynamic changes in facial anatomy during postural shifts is essential.
METHOD: Fresh cadaver studies have demonstrated the passage of threads through the superficial musculoaponeurotic system (SMAS) layer, confirming the efficacy of the technique. Proper insertion depth targeting SMAS repositioning, rather than superficial skin layers, is crucial.
RESULT: The natural movement of tissues secured by thread (N-Cog and N-Fix, N-Finders Inc., Korea) insertion results in lifting effects. However, complications may arise if threads affect deeper facial muscles, leading to discomfort. Fibrous septa play a significant role in guiding thread placement, with different densities influencing thread maneuverability and tissue response during lifting.
CONCLUSION: Procedures targeting SMAS repositioning using threads aim to maintain the new position of relocated tissues. Understanding structural variations in facial regions informs thread selection and placement. Aligning threads with tissue movement and the intended SMAS layer positioning is vital to prevent complications. Balancing thread insertion depth and tissue traction is critical for successful outcomes. Modern thread lifting techniques prioritize SMAS repositioning, enhancing lifting effects while ensuring procedure safety and efficacy.
The degree to which HSV-2 is blocked by the VIBLOK cream is determined by comparing the amount of HSV in the external genital area before and after application of the cream. So participants are their own control.